Higher CBD Concentrations Worsened Inflammatory Markers in Depression in Lab Tests
In vitro testing of CBD on blood from depressed patients and controls found that while low concentrations had no immune effects, higher concentrations paradoxically increased some inflammatory markers and worsened neurotoxicity profiles.
Quick Facts
What This Study Found
CBD at 0.1 mcg/mL had no immune effects. CBD at 1.0 mcg/mL decreased some regulatory immune activity but increased growth factor production. CBD at 10.0 mcg/mL suppressed several immune pathways but also increased IL-1beta, TNF-alpha, and other pro-inflammatory markers. The study concluded there was no beneficial effect of CBD on depression-related immune activation.
Key Numbers
30 depressed patients, 20 controls. CBD 0.1 mcg/mL: no effects. CBD 1.0 mcg/mL: decreased CIRS, increased growth factors. CBD 10.0 mcg/mL: suppressed Th-1, Th-17, IRS, CIRS, neurotoxicity profile but increased IL-1beta, IL-17, TNF-alpha, GM-CSF. Dose-dependent changes in multiple cytokines.
How They Did This
In vitro study using stimulated whole blood from 30 depressed patients and 20 healthy controls. Three CBD concentrations (0.1, 1.0, 10.0 mcg/mL) were tested. Cytokine profiles were measured using LUMINEX assay, covering Th-1, Th-2, Th-17, Treg, IRS, and CIRS pathways.
Why This Research Matters
CBD is widely marketed as anti-inflammatory, but this study found the opposite in the context of depression. If higher CBD concentrations can worsen inflammatory processes, this challenges the assumption that CBD is uniformly beneficial for inflammation-related depression.
The Bigger Picture
This adds nuance to the CBD narrative. The immune system in depression is already dysregulated, and CBD appears to further disrupt it in complex ways that are not simply "anti-inflammatory." This suggests CBD effects on immunity are context-dependent and dose-dependent.
What This Study Doesn't Tell Us
In vitro conditions do not replicate the complexity of the human body. The CBD concentrations may not correspond to plasma levels achieved with typical oral CBD doses. The study used stimulated (not resting) immune cells, which may amplify effects.
Questions This Raises
- ?Do these in vitro immune effects translate to clinically meaningful changes in depressed patients taking CBD?
- ?Would different CBD preparations or combinations with other cannabinoids produce different immune profiles?
Trust & Context
- Key Stat:
- CBD 10 mcg/mL increased IL-1beta, TNF-alpha, and other pro-inflammatory markers
- Evidence Grade:
- Preliminary: in vitro study that may not reflect in vivo conditions.
- Study Age:
- Published in 2022.
- Original Title:
- In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 15(4) (2022)
- Authors:
- Rachayon, Muanpetch, Jirakran, Ketsupar, Sodsai, Pimpayao, Klinchanhom, Siriwan, Sughondhabirom, Atapol, Plaimas, Kitiporn, Suratanee, Apichat, Maes, Michael
- Database ID:
- RTHC-04161
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Does CBD help with depression?
This in vitro study found no beneficial effect of CBD on the inflammatory immune profile seen in depression. Higher concentrations actually increased some pro-inflammatory markers. However, in vitro results do not always predict clinical outcomes.
Is CBD really anti-inflammatory?
CBD has anti-inflammatory effects in some contexts, but this study suggests its immune effects in depression are complex and dose-dependent, with higher concentrations potentially worsening some inflammatory pathways.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04161APA
Rachayon, Muanpetch; Jirakran, Ketsupar; Sodsai, Pimpayao; Klinchanhom, Siriwan; Sughondhabirom, Atapol; Plaimas, Kitiporn; Suratanee, Apichat; Maes, Michael. (2022). In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.. Pharmaceuticals (Basel, Switzerland), 15(4). https://doi.org/10.3390/ph15040405
MLA
Rachayon, Muanpetch, et al. "In Vitro Effects of Cannabidiol on Activated Immune-Inflammatory Pathways in Major Depressive Patients and Healthy Controls.." Pharmaceuticals (Basel, 2022. https://doi.org/10.3390/ph15040405
RethinkTHC
RethinkTHC Research Database. "In Vitro Effects of Cannabidiol on Activated Immune-Inflamma..." RTHC-04161. Retrieved from https://rethinkthc.com/research/rachayon-2022-in-vitro-effects-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.